Aptinyx

Aptinyx R&D per Employee

Delisted

The R&D Spending per Employee of Aptinyx (APTX) as of Oct 24, 2026 is 1.26 M USD. In the previous year, R&D Spending per Employee was 1.63 M USD — a change of -22.90% (lower).

R&D per Employee

1.26 MUSD

YoY

-22.90%

Last updated:

R&D Spending per Employee of Aptinyx is 2022 1.26 M USD. R&D Spending per Employee of Aptinyx was 2021 1.63 M USD. It decreases by -22.90% lower compared to the previous year.

The Aptinyx R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2016
668,911.76 USD
Jan 1, 2017
930,705.88 USD
Jan 1, 2018
1.43 M USD
Jan 1, 2019
1.30 M USD
Jan 1, 2020
965,735.29 USD
Jan 1, 2021
1.63 M USD
Jan 1, 2022
1.26 M USD
The Aptinyx R&D per Employee history
YEARR&D per EmployeeYoY
1.26 MUSD-22.90%
1.63 MUSD+68.86%
965,735.29USD-25.93%
1.30 MUSD-9.14%
1.43 MUSD+54.18%
930,705.88USD+39.14%
668,911.76USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptinyx Stock analysis

What does Aptinyx do? Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptinyx stock

R&D Spending per Employee of Aptinyx is 1.26 M USD in 2022.

R&D Spending per Employee of Aptinyx changed from 1.63 M USD to 1.26 M USD, representing a -22.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Aptinyx since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Aptinyx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Aptinyx

All Key Metrics — Aptinyx